PATENT CLAIM ANALYSIS

Application Number: 15981514
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-09
Patent Classification: ["536", "024310"]

Abstract:
Disclosed herein are methods and reagents for determining the responsiveness of cancer to an epidermal growth factor receptor (EGFR) targeting treatment. The detection of these mutations will allow for the administration of gefitinib, erlotinib and other tyrosine kinase inhibitors to those patients most likely to respond to the drug.

Claim (Index 5):
The assay of  claim 1 , wherein the amplification is by polymerase chain reaction (PCR).

Metadata:
- Claim Count in Document: 33.0
- Percentile: 93.0
- Lexical Diversity: 1.22727
- Patent Class: 536.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14638779', '13896772', '11894160', '11294621', '11894135']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7887403039377018
- 35 USC 102 Novelty (BERT): 0.5696023129183235
- Combined Prediction Score: 0.766826504835764
- Mean Citation Score: 685.39848
- Max Citation Score: 692.37427
- Similarity Product: 347.94109697135866

Labels:
- Claim Label 101: 0
- Claim Label 102: 0
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 0

Dataset: test